Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Personalis Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PSNL
Nasdaq
8731
https://www.personalis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Personalis Inc
Personalis to Announce First Quarter 2024 Financial Results
- Apr 24th, 2024 8:01 pm
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Mar 28th, 2024 8:01 pm
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Mar 28th, 2024 1:00 pm
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
- Mar 26th, 2024 1:00 pm
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 19th, 2024 8:43 pm
Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 2:44 pm
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 28th, 2024 9:01 pm
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
- Feb 14th, 2024 9:01 pm
Personalis to Participate at Upcoming Investor Conferences
- Jan 31st, 2024 9:01 pm
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
- Jan 30th, 2024 2:00 pm
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
- Jan 16th, 2024 2:05 pm
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
- Jan 5th, 2024 2:05 pm
Even With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance Completely
- Dec 18th, 2023 10:33 am
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
- Dec 4th, 2023 2:15 pm
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
- Nov 28th, 2023 9:15 pm
Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript
- Nov 8th, 2023 6:45 pm
Personalis Reports Third Quarter 2023 Financial Results
- Nov 7th, 2023 9:01 pm
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
- Oct 26th, 2023 12:15 pm
Personalis to Announce Third Quarter 2023 Financial Results
- Oct 24th, 2023 8:01 pm
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
- Oct 21st, 2023 8:25 am
Scroll